"Novo Nordisk's Breakthrough Obesity Pill Propels Stock to New Heights"

Novo Nordisk's market value has surpassed Tesla's after positive early trial data for its experimental weight loss pill, amycretin, showed a 13.1% weight loss in participants. The Danish pharmaceutical company's market cap now stands at $604 billion, making it the 12th most valuable company in the world. The company's focus on obesity treatments and cardiovascular disease, along with the potential of its new drugs, has led to a months-long rally in its stock. The company anticipates that the pill could be available to consumers within this decade, and it expects amycretin to have similar cardiac benefits to its successful injection-based drugs, Wegovy and Ozempic.